Search research articles
Contact Us
Filters
Showing results (881-890 of 1,023) with videos related to
Page
of 103
Sort By:
The Journal of School Health
|
April 1, 2025
Understanding Free or Reduced-Price School Meal Stigma: A Qualitative Analysis of Parent Perspectives
Leah Elizabeth Chapman, Wendi Gosliner, Marlene B Schwartz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2023
Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
David S Hong, Michael Postow, Bartosz Chmielowski, et al.
Scientific Reports
|
April 11, 2018
Positive Surgical Margins in the 10 Most Common Solid Cancers
Ryan K Orosco, Viridiana J Tapia, Joseph A Califano, et al.
Journal for Immunotherapy of Cancer
|
September 4, 2025
The spontaneous neoantigen-specific CD4<sup>+</sup> T-cell response to a growing tumor is functionally and phenotypically diverse
Ryan Q Griswold, Spencer E Brightman, Karla Soria Zavala, et al.
Surgical Oncology
|
September 6, 2020
Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerations
David A Barrington, Ashley S Felix, Rieham Owda, et al.
Oral Oncology
|
November 5, 2023
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence
K J Harrington, E E W Cohen, D Soulières, et al.
Health Affairs Scholar
|
May 17, 2024
Parent perceptions of school meals and how perceptions differ by race and ethnicity
Monica D Zuercher, Juliana F W Cohen, Punam Ohri-Vachaspati, et al.
Cancer Research
|
March 26, 2009
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma
Tanguy Y Seiwert, Ramasamy Jagadeeswaran, Leonardo Faoro, et al.
Oral Oncology
|
June 19, 2018
Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma
Renata Ferrarotto, William N William, Jennifer E Tseng, et al.
Biochemistry
|
December 24, 2003
Caveolin-1 null (-/-) mice show dramatic reductions in life span
David S Park, Alex W Cohen, Philippe G Frank, et al.
Page
of 103
Search research articles
Search
Showing results (881-890 of 1,023) with videos related to
Sort By:
Page
of 103
The Journal of School Health
|
April 1, 2025
Understanding Free or Reduced-Price School Meal Stigma: A Qualitative Analysis of Parent Perspectives
Leah Elizabeth Chapman, Wendi Gosliner, Marlene B Schwartz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2023
Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
David S Hong, Michael Postow, Bartosz Chmielowski, et al.
Scientific Reports
|
April 11, 2018
Positive Surgical Margins in the 10 Most Common Solid Cancers
Ryan K Orosco, Viridiana J Tapia, Joseph A Califano, et al.
Journal for Immunotherapy of Cancer
|
September 4, 2025
The spontaneous neoantigen-specific CD4<sup>+</sup> T-cell response to a growing tumor is functionally and phenotypically diverse
Ryan Q Griswold, Spencer E Brightman, Karla Soria Zavala, et al.
Surgical Oncology
|
September 6, 2020
Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerations
David A Barrington, Ashley S Felix, Rieham Owda, et al.
Oral Oncology
|
November 5, 2023
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence
K J Harrington, E E W Cohen, D Soulières, et al.
Health Affairs Scholar
|
May 17, 2024
Parent perceptions of school meals and how perceptions differ by race and ethnicity
Monica D Zuercher, Juliana F W Cohen, Punam Ohri-Vachaspati, et al.
Cancer Research
|
March 26, 2009
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma
Tanguy Y Seiwert, Ramasamy Jagadeeswaran, Leonardo Faoro, et al.
Oral Oncology
|
June 19, 2018
Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma
Renata Ferrarotto, William N William, Jennifer E Tseng, et al.
Biochemistry
|
December 24, 2003
Caveolin-1 null (-/-) mice show dramatic reductions in life span
David S Park, Alex W Cohen, Philippe G Frank, et al.
Page
of 103